[go: up one dir, main page]

MX2019009356A - Sulfinilpiridinas y su uso en el tratamiento del cancer. - Google Patents

Sulfinilpiridinas y su uso en el tratamiento del cancer.

Info

Publication number
MX2019009356A
MX2019009356A MX2019009356A MX2019009356A MX2019009356A MX 2019009356 A MX2019009356 A MX 2019009356A MX 2019009356 A MX2019009356 A MX 2019009356A MX 2019009356 A MX2019009356 A MX 2019009356A MX 2019009356 A MX2019009356 A MX 2019009356A
Authority
MX
Mexico
Prior art keywords
treatment
sulfinylpyridines
cancer
compounds
cancers
Prior art date
Application number
MX2019009356A
Other languages
English (en)
Inventor
Pelcman Benjamin
Orwar Owe
Stafford William
Anderson Kjell
Original Assignee
Oblique Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oblique Therapeutics Ab filed Critical Oblique Therapeutics Ab
Publication of MX2019009356A publication Critical patent/MX2019009356A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan compuestos de la Fórmula I (I) (ver formula I) o sales de estos aceptables desde el punto de vista farmacéutico, en donde L, R1, R2, R3, R4 y n tienen significados proporcionados en la descripción, en donde los 10 compuestos son útiles en el tratamiento de tipos de cáncer.
MX2019009356A 2017-02-07 2018-02-07 Sulfinilpiridinas y su uso en el tratamiento del cancer. MX2019009356A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762455645P 2017-02-07 2017-02-07
PCT/GB2018/050342 WO2018146468A1 (en) 2017-02-07 2018-02-07 Sulfinylpyridines and their use in the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2019009356A true MX2019009356A (es) 2019-09-19

Family

ID=61226605

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009356A MX2019009356A (es) 2017-02-07 2018-02-07 Sulfinilpiridinas y su uso en el tratamiento del cancer.

Country Status (12)

Country Link
US (2) US11208384B2 (es)
EP (1) EP3580204A1 (es)
JP (1) JP2020507624A (es)
KR (1) KR20190115011A (es)
CN (1) CN110382465A (es)
AU (1) AU2018218518B2 (es)
BR (1) BR112019016258A2 (es)
CA (1) CA3051644A1 (es)
MA (1) MA47450A (es)
MX (1) MX2019009356A (es)
RU (1) RU2019127896A (es)
WO (1) WO2018146468A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
CN110382465A (zh) * 2017-02-07 2019-10-25 欧比力克治疗公司 亚磺酰基吡啶和其在癌症治疗中的用途
EP3580209A1 (en) 2017-02-07 2019-12-18 Oblique Therapeutics AB Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
CA3051537A1 (en) 2017-02-07 2018-08-16 Oblique Therapeutics Ab Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer
CN110382464A (zh) 2017-02-07 2019-10-25 欧比力克治疗公司 烃基磺酰基取代的吡啶和其在癌症治疗中的用途
JP2021513573A (ja) * 2018-02-12 2021-05-27 シンダ ファーマ エービー 癌の処置に使用されるチオレドキシン還元酵素阻害剤

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3064846D1 (en) 1979-12-19 1983-10-20 Duphar Int Res New nitrothiophenes, method of preparing the new compounds, as well as fungicidal and/or bactericidal compositions on the basis of the new compounds
US4456469A (en) 1980-03-07 1984-06-26 E. I. Du Pont De Nemours And Company Pyridyl sulfone herbicides
AU543161B2 (en) 1980-03-07 1985-04-04 E.I. Du Pont De Nemours And Company Pyrimidine or s.triazine derivatives
US4791127A (en) 1985-10-07 1988-12-13 Nippon Kayaku Kabushiki Kaisha Alkanesulfonate derivatives and their use as insecticides, acaricides or nematicides
DE3812177A1 (de) * 1988-04-13 1989-10-26 Bayer Ag 2-phenylsulfinyl-nitro-pyridine, verfahren zu ihrer herstellung und ihre verwendung
WO1995029897A1 (en) 1994-04-29 1995-11-09 G.D. Searle & Co. METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS
DE19531148A1 (de) 1995-08-24 1997-02-27 Basf Ag Fungizide Pyridin-2-yl-Derivate
US6069144A (en) 1995-08-24 2000-05-30 Basf Aktiengesellschaft N-heterocyclic compounds, intermediate products used to prepare them, agents containing them and their use in antifungal applications
EP0984935A1 (de) 1997-05-30 2000-03-15 Basf Aktiengesellschaft Verfahren zur herstellung substituierter thiopyridine
US6284923B1 (en) 1997-08-22 2001-09-04 Tularik Inc Substituted benzene compounds as antiproliferative and cholesterol lowering action
AU9781098A (en) 1997-10-02 1999-04-27 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6191170B1 (en) 1998-01-13 2001-02-20 Tularik Inc. Benzenesulfonamides and benzamides as therapeutic agents
DE69906397T2 (de) 1998-01-16 2004-02-19 F. Hoffmann-La Roche Ag Benzosulfonderivate
US6376515B2 (en) 2000-02-29 2002-04-23 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor Xa
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2003211427A1 (en) 2002-02-18 2003-09-04 Ishihara Sangyo Kaisha, Ltd. Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
US7037902B2 (en) * 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
EP1651595A2 (en) 2003-05-30 2006-05-03 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
WO2005121121A2 (en) 2004-06-04 2005-12-22 Arena Pharmaceuticals, Inc. Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20060019967A1 (en) * 2004-07-21 2006-01-26 Su-Ying Wu SARS CoV main protease inhibitors
GB0426313D0 (en) 2004-12-01 2005-01-05 Merck Sharp & Dohme Therapeutic agents
WO2006083692A2 (en) 2005-01-28 2006-08-10 Mount Sinai Schoool Of Medicine Methods of identifying modulators of bromodomains
GB0504828D0 (en) 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
US20100048713A1 (en) 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
JP2009535307A (ja) 2006-04-28 2009-10-01 アベキサ・リミテッド インテグラーゼ阻害剤３
EP2061472A4 (en) * 2006-05-22 2010-12-22 Thioredoxin Systems Ab BACTERIAL THIOREDOXINE REDUCTASE INHIBITORS AND METHODS OF USING THE SAME
MX2010000617A (es) 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
CN101723932B (zh) 2008-10-31 2013-11-20 北京以岭生物工程技术有限公司 硝基吡啶乙烯亚胺化合物、其药物组合物及其制备方法和用途
US9421211B2 (en) * 2009-05-28 2016-08-23 President And Fellows Of Harvard College N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation
NZ713361A (en) 2009-08-17 2017-06-30 Memorial Sloan Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
US9206125B2 (en) 2010-02-10 2015-12-08 Public University Corporation Yokohama City University Use of compound binding to mSin3B that specifically binds to neuron restrictive silencer factor (NRSF)
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
WO2012025638A1 (en) 2010-08-27 2012-03-01 Universität des Saarlandes Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors
CN104220053B (zh) 2012-02-10 2017-05-03 德克萨斯大学系统董事会 cAMP直接活化交换蛋白(EPAC)的调节剂
US8946418B1 (en) 2013-07-10 2015-02-03 Boehringer Ingelheim International Gmbh Chiral nitrogen-phosphorus ligands and their use for asymmetric hydrogenation of alkenes
CN104672214B (zh) 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
CN105503827B (zh) 2014-10-11 2019-09-24 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备方法和用途
CN104987324B (zh) 2015-06-04 2018-05-04 湖北生物医药产业技术研究院有限公司 作为alk抑制剂的嘧啶衍生物
CN105085483B (zh) 2015-06-04 2019-01-01 湖北生物医药产业技术研究院有限公司 激酶抑制剂及其应用
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
EP3580209A1 (en) 2017-02-07 2019-12-18 Oblique Therapeutics AB Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
CA3051537A1 (en) 2017-02-07 2018-08-16 Oblique Therapeutics Ab Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer
CN110382464A (zh) 2017-02-07 2019-10-25 欧比力克治疗公司 烃基磺酰基取代的吡啶和其在癌症治疗中的用途
CN110382465A (zh) * 2017-02-07 2019-10-25 欧比力克治疗公司 亚磺酰基吡啶和其在癌症治疗中的用途

Also Published As

Publication number Publication date
US11208384B2 (en) 2021-12-28
AU2018218518A1 (en) 2019-08-15
EP3580204A1 (en) 2019-12-18
US20200024233A1 (en) 2020-01-23
CA3051644A1 (en) 2018-08-16
US20220177430A1 (en) 2022-06-09
JP2020507624A (ja) 2020-03-12
MA47450A (fr) 2019-12-18
RU2019127896A3 (es) 2021-05-18
CN110382465A (zh) 2019-10-25
BR112019016258A2 (pt) 2020-04-07
AU2018218518B2 (en) 2022-03-17
RU2019127896A (ru) 2021-03-09
KR20190115011A (ko) 2019-10-10
WO2018146468A1 (en) 2018-08-16

Similar Documents

Publication Publication Date Title
ZA202405294B (en) Heterocyclic compounds as immunomodulators
ZA202206806B (en) Benzooxazole derivatives as immunomodulators
MX2019009356A (es) Sulfinilpiridinas y su uso en el tratamiento del cancer.
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
MX389800B (es) Piridinas sustituidas con heterociclilsulfonilo y su uso en el tratamiento del cancer
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
MX392900B (es) Piridinas sustituidas con hidrocarbilsulfonilo y su uso en el tratamiento del cancer
PH12019550224A1 (en) Antitumoral compounds
MX392026B (es) Compuestos heterocíclicos como inmunomoduladores.
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
PH12018502497A1 (en) Adenosine derivatives for use in the treatment of cancer
MX2015010128A (es) Derivados de piridazinona macrociclicos.
MX391999B (es) Piridinas y su uso en el tratamiento del cáncer.
MX2018008362A (es) Derivados de quinolin-2-ona.
MX392000B (es) Piridinas sustituidas con heteroarilsulfonilo y su uso en el tratamiento del cáncer.
PH12020551543A1 (en) Therapeutic modulators of the reverse mode of atp synthase
AU2016363719A8 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
WO2017027357A8 (en) Pyridazinones and their use in the treatment of cancer
WO2017027358A8 (en) Tricyclic compounds and their use in the treatment of cancer
EA201992557A1 (ru) Противоопухолевые соединения
MX2024010153A (es) Moduladores terapeuticos del modo inverso de la atp sintasa.